Noninvasive testing may predict portal hypertension, clinical outcomes in cured HCV

LONDON — Noninvasive testing may predict clinically significant portal hypertension and other outcomes in patients after hepatitis C virus cure, according to research presented at the International Liver Congress.“The presence of clinically significant portal hypertension determines decision treatment with nonselective beta-blockers in compensated, advanced chronic liver disease,” Georg Semmler, MD, PhD, of the Medical University of Vienna, said. “It’s important to know whether the patient has clinically significant portal hypertension or not. However, hepatic venousRead More

Categories: News

Related Articles

Rapid treatment significantly increases HCV cure rate among injection drug users

A rapid treatment model that included a 7-day starter pack of medication significantly increased hepatitis C cure rates among young people who inject drugs, according…

HCV reinfection prevalence rises among MSM as acute cases decline

LONDON — Although the annual incidence of acute hepatitis C virus has decreased over the past 10 years in Frankfurt, Germany, the prevalence of HCV…

Givosiran increases quality of life, reduces attacks in acute hepatic porphyria

LONDON — Long-term givosiran treatment provided sustained benefit and improved quality of life among patients with acute hepatic porphyria, according to research presented at the…

Bulevirtide monotherapy safe, well-tolerated in chronic hepatitis D patients

LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according…

DAA use decreases risk for cardiovascular events in patients with advanced fibrosis, HCV

LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased…